The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just shows how quickly even the quietest stock on the market can turn. Just last week people were selling below the bid at 19p. I knew this was cheap. It took a while for them to sell the supermarket business but they have and now have a cash surplus worth well over 35p so it's quickly catching up. Shame I have a tiny holding but I'm not complaining.
;-) Yeah, nearly £30K from probably one person. Ticking up.
A sudden bit of interest in the last hour. Maybe someone else has just finished reading up on this one!
Yes, need to look into this more. Kicking self for not looking properly earlier.
Couple of encouraging RNS' Will do some more reading on this one.
I put it down to boredom and this stock off the radar. Just look at that appointment today he seems solid enough and I wonder if he was appointed in other more popular bios what would have been the reaction. And to think we have a 28p 100k recent director buy as well not often they trade lower after that. As always I talk to myself with this stock and a little baffled at the lack of interest with pi's when you have a company covered by so much cash that seems to have a great fresh business which could be floated or sold off soon and has drugs close to clinical trials.
Thanks for your reply, must admit I'm quite tempted but there is still some drip drip selling going on, dosent inspire tbh, think I will watch from the sidelines for a bit longer, may miss my chance but that's the gamble, gl
I was in shock when I saw another post. There was 2 new ones the other day but somebody posted here by mistake and they were removed. Agreed with the boredom. If this was say 2.55-2.65p with 10 times more shares in issue there would be regular trades and lots of posts and holders. It really is off the menu but I hold waiting for that Rns soon of a surprise price for the Fresh business then everybody will be trying to buy in when 30-50% higher, well that is my take on it. The large director buy at 28p gives me condifence, can only assume the selling afterwards was end of tax year. If you check website there is 2 products almost ready for clinical trials, it's amazing what a Rns for those to start will do to a price although not as exciting as SAR's cancer products. All backed by high cash levels. I cannot see the downside.....all boxes ticked just a big dose of patience
I look in here from time to time, catch up with your conversations, would join ya but think the boredom would destroy what little patience I have remaining
So the chief ex buys 100,000 at 28p paying a premium at the time and the mm's are shaking this back down on no trade. I hope he buys more or other directors do but in honesty they have all been heavy buyers in the last 12 months but it would be nice if the new appointment mr Gill weighs in with his first holding. Still remains incredibly cheap with cash covering most of the market cap with a retail business about to be sold or spun off which could fetch anything up to £15 mil imo based on what they got for the last sale of a business.
Nobody else here holds this but this seems a one way ticket now after director buying heavy for first time ever and paying a 1p premium to get size of 100k. Just a steady uptrend towards 30p waiting for the supermarket news and that might give it the spike to 40p we shall see
My biggest holding by far whilst the gap between cash and market cap remains so tiny. Recent new management signing says they are gearing up for Phase 1 trials to begin end of the year or early 2017 and of course they will offload or float the Fresh business which might fetch a surprise high price leaving this one of the rare cases of a biotech holding way more cash than market cap although if this does happen the price will be marked up heavily. Nothing is certain and like all stocks there's risks but one I like to gamble heavily on while the market cap remains just a fraction about their cash which is ridiculous given the growth in the fresh business.
Sale of Endoscopy business was done when the shareprice was 30p in June of 2014 and the price spiked up to 50p on this news. So what price in a sale will Steriloxfresh achieve considering it's sales are now almost the same as Endoscopy. Endoscopy got a massive $26.9 mil cash sale for $23.3 of sales and PBT of $2.1 mil. Interesting the recent trading update puts sales at $23.4 mil which is mostly Steriloxfresh and Puri management are now looking to float or sell the business so there could be a real surprise Rns which will boost the shares if they manage to get a nice price for it in a sale or even a float should have the same reaction.
Hopefully when everybody else catches on to this it will be 35-40p
Interesting that one every bb and twitter feed almost there is a buzz for ONZ because the market cap is tiny and they are trying to branch into exciting new bio markets and maybe there is a good case to argue it's cheap. Then I look (yet again) at my investment in Puri to make sure I'm seeing it correctly. Market cap £12.28 mil, $15.5 mil of cash which equates to £10.89 mil so if you take out the cash that leaves a value of £1.39 mil And they have a rapidly growing business which has just increased turnover 36% to $23 mil. And this retail business they are looking to float/sell so potential there for another massive increase in cash. Oh and then that leaves the bio side of the business...in last trading update...I think the trading patterns speak for themselves, all the trades are small impatient sellers now and again and then there is a massive buy which hoovers it all up. Smart money is buying... The conclusion of the strategic review has been to initiate a drug development program based on PuriCore's patented hypochlorous acid technology and formulations at high concentration. During the review, the Company generated compelling evidence in preclinical studies that these formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas such as Dermatology and Ophthalmology, including certain orphan indications. In relevant animal models of disease, for instance, application of the formulations resulted in a statistically significant impact on allergen-induced itch and inflammation associated with atopic dermatitis (including evidence of the inhibition of key cytokines), as well as hyperemia (red eye) associated with allergic conjunctivitis. This work builds upon previous clinical experience with the Company's medical devices in Wound Care and Dermatology. In parallel to the preclinical work, the Company worked with a leading pharmaceutical consulting firm to complete a comprehensive drug development strategic review. This review, involving influential key opinion leaders (KOLs), focused on unmet medical needs with considerable commercial value and resulted in the development of a product pipeline in several therapeutic areas based on formulations containing the Company's proprietary immunomodulatory technology. In 2016, the Company is continuing formulation development and conducting a series of additional preclinical and toxicology studies in support of the planned Investigational New Drug (IND) filings. It is expected that, if successful, clinical development and subsequent New Drug Application (NDA) filing(s) with the FDA will lead to novel prescription medicines for commercially attractive and underserved markets. On current timelines, the Company expects to file two IND applications with the FDA in Q1 2017 and commence clinical testing thereafter. The Company has a search underway for a Chief Medical Officer to support these goals
Think this could be the bargain of bargains not without risks of course. The current market cap is almost covered by cash. They have options with their strong growing supermarket business which could be a sale which would do wonders for the shareprice having another cash boost yet it still leaves another business in the bio field which seems to be progressing well. Take out cash and it's incredible that all this is currently being valued at 1 million. To keep things level there is some kind of investigation going on into their concentrate products not sure the outcome of that. Lets hope at worst it's a small find but these seem to represent amazing value which is totally off the radar to pi's as it's a very quiet stock most of the time.
Off a email to the company. I find the valuation hard to understand. Everything is being valued at almost zero. Just want to see if the company directors feel the same way.
So 15 mil USD is £10.5 mil so strip out cash you get £2 mil market cap for this business. Scary numbers even with the litigation mentioned in statement. Price should easily north of 40p never mind 30p
Let's hope that they spin out the supermarket business and not sell it. If they sell it the money will just go to the company, if we the existing shareholders get it then it will be some sort of safeguard whilst they attempt to develop the new business.
Looking exciting here . $23m Rev $15m net cash £11m mcap Potential spin out of supermarket business = $$s
again, looking good this morning
FINANCIAL HIGHLIGHTS · Group revenue increased 5.9% to $9.1m (H1 2014:$8.6m) - Supermarket Retail revenue increased 9.3% to $8.4m (H1 2014: $7.7m) driven by higher sales of consumable products - As expected, Health Sciences revenue decreased to $0.3m (H1 2014: $0.9m) following the termination of the Onset Dermatologics partnership agreement, as previously announced, in December 2014 - Other revenue increased to $0.4m (H1 2014: nil) and represents fees paid by third parties to gain letters of access to the Active Chlorine Biocidal Products Regulation (BPR) dossier · Gross margin decreased to 24.5% (H1 2014: 28.2%) due to increased service costs within Supermarket Retail - Company remains focused on improving margins in the mid- term and is investing in improving the reliability of its generators and updating early versions of its concentrate delivery system · Operating expenses increased to $6.9m (H1 2014: $6.1m) due primarily to investment in research, development and regulatory activities in Health Sciences and Supermarket Retail · EBITDA* loss $3.8m (H1 2014 loss: $2.2m) · Cash and cash equivalents, net of debt ($0.2m), were $16.3m as at 30 June 2015 (as at 31 December 2014: $20.7m, net of debt) *** Current mcap sits at £10m - cash and cash equivalants at USD 16m + HY1 sales of USD $9.1m
Good to see interest here, been holding for a few months and looks significantly undervalued at these levels. 2 significant director buys in recent months. Looking forward to market update
Very recently I invested in what I believe to be 4 value stocks on the AIM - Weatherly International, Range Resources, Oxford Biomedica and Puricore. £2000 in each. Wish me luck guys - any positive views welcomed.
FINANCIAL HIGHLIGHTS · Group revenue increased 5.9% to $9.1m (H1 2014:$8.6m) - Supermarket Retail revenue increased 9.3% to $8.4m (H1 2014: $7.7m) driven by higher sales of consumable products - As expected, Health Sciences revenue decreased to $0.3m (H1 2014: $0.9m) following the termination of the Onset Dermatologics partnership agreement, as previously announced, in December 2014 - Other revenue increased to $0.4m (H1 2014: nil) and represents fees paid by third parties to gain letters of access to the Active Chlorine Biocidal Products Regulation (BPR) dossier · Gross margin decreased to 24.5% (H1 2014: 28.2%) due to increased service costs within Supermarket Retail - Company remains focused on improving margins in the mid- term and is investing in improving the reliability of its generators and updating early versions of its concentrate delivery system · Operating expenses increased to $6.9m (H1 2014: $6.1m) due primarily to investment in research, development and regulatory activities in Health Sciences and Supermarket Retail · EBITDA* loss $3.8m (H1 2014 loss: $2.2m) · Cash and cash equivalents, net of debt ($0.2m), were $16.3m as at 30 June 2015 (as at 31 December 2014: $20.7m, net of debt) *** Current mcap sits at £10m - cash and cash equivalants at USD 16m + HY1 sales of USD $9.1m